BioCryst Pharmaceuticals
BCRX
#4531
Rank
ยฃ1.88 B
Marketcap
ยฃ7.41
Share price
2.83%
Change (1 day)
13.51%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of March 2026 : ยฃ0.61 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is ยฃ0.61 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2026)

Total debt by year

Year Total debt Change
2025-12-31ยฃ0.32 B-49.43%
2024-12-31ยฃ0.64 B-0.5%
2023-12-31ยฃ0.64 B5.68%
2022-12-31ยฃ0.61 B39.45%
2021-12-31ยฃ0.43 B114.33%
2020-12-31ยฃ0.20 B217.64%
2019-12-31ยฃ64.55 M32.55%
2018-12-31ยฃ48.7 M20.29%
2017-12-31ยฃ40.48 M-7.01%
2016-12-31ยฃ43.53 M113.8%
2015-12-31ยฃ20.36 M5.69%
2014-12-31ยฃ19.26 M5.95%
2013-12-31ยฃ18.18 M-2.01%
2012-12-31ยฃ18.56 M-3.84%
2011-12-31ยฃ19.3 M
2000-12-31ยฃ0 M
1997-12-31ยฃ0.06 M-65.25%
1996-12-31ยฃ0.17 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Gilead Sciences
GILD
ยฃ16.72 B 2,611.53%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
ยฃ19.03 B 2,986.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
ยฃ0.78 B 26.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
ยฃ0.51 B-15.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
ยฃ0.22 B-63.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
ยฃ1.43 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
ยฃ1.13 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
ยฃ7.07 M-98.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
ยฃ0.50 B-18.91%๐Ÿ‡บ๐Ÿ‡ธ USA